Fig. 1: The cost-effectiveness plane from the health care payer's perspective. | npj Vaccines

Fig. 1: The cost-effectiveness plane from the health care payer's perspective.

From: Cost-effectiveness of maternal vaccine and/or monoclonal antibody strategies against respiratory syncytial virus in Belgian infants

Fig. 1: The cost-effectiveness plane from the health care payer's perspective.

QALY quality-adjusted life year, EUR euro, MV year-round maternal vaccine, MV Sep-Mar seasonal maternal vaccine from September to March, NmAb year-round nirsevimab, NmAb: Oct-Mar seasonal NmAb strategy from October to March, NmAb: Oct-Mar + catch-up seasonal NmAb combined with a catch-up strategy.

Back to article page